Calidi Biotherapeutics Management

Management Kriterienprüfungen 4/4

Calidi Biotherapeutics CEO ist Allan Camaisa , ernannt in Feb 2018, hat eine Amtszeit von 6.75 Jahren. Die jährliche Gesamtvergütung beträgt $436.51K , bestehend aus 58.9% Gehalt und 41.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.4% der Aktien des Unternehmens, im Wert von $148.05K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.8 Jahre bzw. 3.8 Jahre.

Wichtige Informationen

Allan Camaisa

Geschäftsführender

US$436.5k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	58.9%
Amtszeit als Geschäftsführer	6.8yrs
Eigentum des Geschäftsführers	0.4%
Durchschnittliche Amtszeit des Managements	6.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Allan Camaisa im Vergleich zu den Einnahmen von Calidi Biotherapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$437k	US$257k	-US$29m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$24m
Dec 31 2022	US$2m	US$43k	-US$25m
Sep 30 2022	n/a	n/a	-US$21m
Dec 31 2021	US$1m	US$26k	-US$11m

Vergütung im Vergleich zum Markt: AllanDie Gesamtvergütung ($USD436.51K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD647.72K).

Entschädigung vs. Einkommen: AllanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Allan Camaisa (64 yo)

6.8yrs

Amtszeit

US$436,512

Vergütung

Mr. Allan J. Camaisa serves as Chief Executive Officer and Chairman of the Board at Calidi Biotherapeutics, Inc since February 2018. He served as Chief Executive Officer and Chairman at Parallel 6, Inc. si...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 148.1k
Wendy Pizarro Campbell	Chief Administrative Officer	3.2yrs	US$295.40k	0.084% $ 31.3k
Boris Minev	President of Medical & Scientific Affairs and Interim Chief Medical Officer	9.4yrs	US$400.10k	0.22% $ 81.9k
Andrew Jackson	Chief Financial Officer	1.1yrs	keine Daten	keine Daten
Stephen Thesing	Chief Business Officer	8.8yrs	keine Daten	0.24% $ 91.0k

6.8yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: CLDIDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 148.1k
James Schoeneck	Independent Director	4.3yrs	US$109.56k	0.53% $ 197.4k
W.K. Yung	Member of Medical Advisory Board	2.4yrs	keine Daten	keine Daten
Ewa Carrier	Member of Medical Advisory Board	no data	keine Daten	keine Daten
George Peoples	Independent Director	less than a year	keine Daten	0.00089% $ 331.8
Scott Leftwich	Independent Vice-Chairman of the Board	5.5yrs	US$179.89k	1.23% $ 459.1k
Alan Stewart	Independent Director	1.1yrs	US$120.56k	0.029% $ 10.7k
Santosh Kesari	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Dmitriy Zamarin	Member of Scientific Advisory Board	3.8yrs	keine Daten	keine Daten
Ashok Srivastava	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Karen Aboody	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Maciej Lesniak	Member of Medical Advisory Board	no data	keine Daten	keine Daten

3.8yrs

Durchschnittliche Betriebszugehörigkeit

63.5yo

Durchschnittliches Alter

Erfahrener Vorstand: CLDIDie Vorstandsmitglieder gelten als erfahren (3.8 Jahre durchschnittliche Amtszeit).

Calidi Biotherapeutics Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Recent updates

Calidi Biotherapeutics Inc. Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.499999 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Less than half of directors are independent

Calidi Biotherapeutics Announces Directorate Changes

Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board

New major risk - Financial position

New major risk - Shareholder dilution

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer

Less than half of directors are independent

Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. announced that it has received funding from Jackson Investment Group, Calidi Cure, LLC

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter